ACE2 and diabetes mellitus: The activity of ACE2 is increased in DM mice 164, 165 and significantly increased in patients with DM treated with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 166, suggesting that patients with DM may be at increased COVID-19 risk.